ArticleJournal of translational medicine2025
Colorectal cancer epidemiology (1990-2050): lessons from the Australasian experience.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative In Silico and FFPE Tissue Analyses Elucidate Upregulated Genes in Colorectal Cancer Enriched for Tie2-Expressing Macrophages/Monocytes.International journal of molecular sciences · 2026Article
- Global burden of colorectal cancer from 1990 to 2021: a systematic analysis from the Global Burden of Disease Study 2021.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCRC is regarded as a worldwide health issue, exhibiting considerable geographic differences. The current research examines the global epidemiology of CRC (1990-2021) and forecasts trends until 2050, focusing specifically on Australasia.
methodsWe performed an extensive analysis using data from the Global Burden of Disease 2021 study to calculate age-standardized incidence and mortality rates (ASIR/ASMR) for CRC from 1990 to 2021. Analyses were divided by sex, age, geographic area, and SDI. Temporal trends were evaluated by utilizing EAPC. We assessed the impact linked to significant modifiable risk factors such as dietary risks, elevated body mass index, alcohol consumption, smoking, and lack of physical activity using comparative risk evaluation techniques. To forecast CRC mortality until 2050, we utilized a Bayesian Age-Period-Cohort (BAPC) model that includes demographic and temporal factors.
resultsRegions with high SDI exhibit the highest incidence of CRC but show decreasing trends, whereas regions with middle SDI are experiencing increasing burdens. Australasia, despite its historically high rates, accomplished notable reductions in mortality (-1.95% per year), positioning itself alongside Austria and Germany as frontrunners in CRC management. The rate of CRC occurrence is believed to be greater in males than in females. Dietary elements are the primary alterable risk factor worldwide, particularly in affluent areas. Forecasts and future estimates indicate additional declines in mortality rates in high-income areas, while transitioning economies face rising burdens.
conclusionThe burden of CRC is moving towards developing areas. Australasia showcases effective cancer management via screening and treatment, offering essential insights for global policies and strategies addressing changeable risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.